About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Chairperson's Speech 2018
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2019

Annual Report 2018

  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery


Biocon Malaysia




  Facilities Virtual Tour

Biocon is Asia’s premier fun88官网 company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia and Japan. Our credibility as a serious player in the biosimilars sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first globally to get biosimilar Trastuzumab and Pegfilgrastim approved in the U.S. in 2017 and 2018, respectively. We were also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. We have also established our presence in key emerging markets through safe, effective and high quality biosimilars including recombinant human insulin.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global fun88官网s player.



Biocon Performance Highlights of Q4 and FY19 by Kiran Mazumdar-Shaw, CMD, Biocon Ltd.

Biocon Corporate Overview


Company Announcements


July 08, 2019 
Pre -Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia

May 22, 2019 
Health Canada Approves Biocon and Mylan's Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers

May 16, 2019 
Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin ®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2019
Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr

  Media Coverage  

Jun 18, 2019:
Biosimilars, research key drivers for Biocon

Jun 18, 2019:
Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

Jun 15, 2019:
Biocon’s Bengaluru biologics units get European agency nod

Jun 8, 2019:
The First Lady of Biotech







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved